Idatha Entsha Nge-Ulcerative Colitis

I-Protagonist Therapeutics namuhla imemezele imiphumela ephezulu evela ocwaningweni lweSigaba 2 lwe-IDEAL oluhlola i-PN-943 ezigulini ezine-ulcerative colitis (UC) ephakathi kuya kwembi.

"Sijabule ngamandla emiphumela evela ocwaningweni lwe-IDEAL futhi sibheke phambili ekusebenzisaneni nezinhlaka ezilawulayo njengoba silungiselela uhlelo lokubhalisa lweSigaba 3 se-PN-943 ku-ulcerative colitis emaphakathi kuya kokuqina," kusho u-Dinesh V. U-Patel, Ph.D., uMongameli kanye Nesikhulu Esiphezulu Sommeleli. “Umenzeli wethu we-alpha-4-beta-7-integrin omelene nomlomo, okhawulelwe emathunjini u-PN-943 ubonise ukusebenza ngempumelelo komtholampilo ngokuhambisana nomuthi ovunyelwe wokulwa negciwane lengculazi osebenza ngendlela efanayo yebhayoloji. Sikholelwa ukuthi imiphumela yocwaningo lwe-IDEAL ingase ishintshe i-paradigm kanye nokuhambisana okubanzi kwesayensi ekuqondeni i-IBD pathogenesis kanye nokuthuthukiswa kwezidakamizwa ezikhawulelwe emathunjini ngokungenelela kwendlela ye-integrin-MAdCAM. Ngokusekelwe ekululameni kwayo kokuphathwa ngomlomo kanye nokusebenza kahle nemiphumela yokuphepha ephawulwe kuze kube manje, sikholelwa ukuthi i-PN-943 inamandla okuba umuthi womlomo osezingeni lokuqala, oyisisekelo kubantu abanesifo sokuqaqamba kwamathumbu esilonda esiswini esimaphakathi kuya kokubi kakhulu. .”

"Ngocwaningo lwe-IDEAL, sibonise ubufakazi bomtholampilo kanye nokuqinisekiswa kokwelashwa okungase kube khona kwe-ulcerative colitis ngokusebenzisa ngomlomo, ukuvinjelwa kwamathumbu okuvinjelwe kwendlela ye-alpha-4-beta-7-integrin," kusho uScott Plevy, MD. Iphini Likamongameli Omkhulu kanye Nenhloko Yezokwelapha Ye-Gastroenterology ku-Protagonist. “Ucwaningo luhlole imithamo emibili ye-PN-943, 150 mg BID kanye ne-450 mg BID, futhi lwabonisa umphumela wokwelapha ocacile futhi ongaguquki kumthamo ophansi we-150 mg BID kuzo zonke iziphetho ezibalulekile. Impendulo yethamo ekhonjiswa yilolu cwaningo ihambisana nezinye izindlela ezimbalwa endleleni ye-integrin. Okutholwe engalweni enethamo eliphansi kunikeza ubufakazi obungaguquki bokusebenza ngempumelelo emtholampilo kanye nokuphepha, kanye nesiqondiso esicacile sohlobo lomthamo wohlelo lokubhalisa lweSigaba 3.”

"I-ejenti yomlomo, ekhawulelwe emathunjini i-PN-943 ibonakala inemiphumela efanayo kumthamo we-150 mg kabili ngosuku uma kuqhathaniswa nomuthi omjovo omjovo we-alpha-4-beta-7-integrin kanye nendlela yokusebenza kwawo," kusho uBruce Sands. , MD, MS, uDkt. Burrill B. Crohn Uprofesa Wezokwelapha e-Icahn School of Medicine eNtabeni yaseSinayi, umphenyi oyinhloko wesifundo se-IDEAL kanye nomxhumanisi ku-Protagonist. "Kunesidingo esicacile esingahlangabeziwe kanye nenzuzo eqinile yomtholampilo ezigulini ezine-ejenti yomlomo esebenza ngale ndlela eqondile ye-IBD efakazelwe, futhi imiphumela yocwaningo lwe-IDEAL inikeza isizathu esihle sokuqhubekisela phambili i-PN-943 ocwaningweni lokubhalisa lweSigaba 3."